SLC16A7 Knockout HCT 116 Cell Line
Cat.No.:
EDC08384
Species:
Human
Cell Name:
HCT 116
Gene:
SLC16A7
Gene ID:
9194
Size:
1×10⁶cells
SLC16A7 Knockout Cell Line (HCT116) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDC08384 |
|---|---|
| Product Name | SLC16A7 Knockout HCT 116 Cell Line |
| Cell Line | HCT 116 |
| Cellosaurus ID | CVCL_0291 |
| Cell Line Synonyms | HCT-116, HCT.116, HCT_116, HCT116, HCT116wt, HCT-116/P, HCT-116/parental, CoCL2 |
| Gene | SLC16A7 |
| NCBI Gene ID | |
| Gene Synonyms | MCT2 |
| Summary |
This gene is a member of the monocarboxylate transporter family. Members in this family transport metabolites, such as lactate, pyruvate, and ketone bodies. The protein encoded by this gene catalyzes the proton-linked transport of monocarboxylates and has the highest affinity for pyruvate. This protein has been reported to be more highly expressed in prostate and colorectal cancer specimens when compared to control specimens. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2012]
|
| Associated Diseases | Colorectal Carcinoma |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HCT 116 | STR Info (Cell bank) Cell Line: HCT 116 | ||||||
| Allele1 | Allele2 | Allele3 | Allele4 | Allele1 | Allele2 | Allele3 | Allele4 | |
| Amelogenin | X | X | ||||||
| CSF1PO | 7 | 10 | 7 | 9 | 10 | 11 | ||
| D2S1338 | 16 | 16 | ||||||
| D3S1358 | 12 | 17 | 18 | 19 | 12 | 18 | 19 | |
| D5S818 | 10 | 11 | 10 | 11 | ||||
| D7S820 | 11 | 12 | 11 | 12 | ||||
| D8S1179 | 10 | 12 | 14 | 15 | 10 | 12 | 14 | 15 |
| D13S317 | 10 | 12 | 10 | 12 | ||||
| D16S539 | 11 | 13 | 11 | 12 | 13 | 14 | ||
| D18S51 | 16 | 17 | 16 | 17 | ||||
| D19S433 | 12 | 13 | 12 | |||||
| D21S11 | 29 | 30 | 29 | 30 | ||||
| FGA | 18 | 23 | 18 | 23 | ||||
| Penta D | 9 | 13 | 9 | 13 | ||||
| Penta E | 12 | 13 | 14 | 12 | 13 | 14 | ||
| TH01 | 8 | 9 | 8 | 9 | ||||
| TPOX | 8 | 8 | ||||||
| vWA | 17 | 21 | 22 | 23 | 17 | 21 | 22 | 23 |
| D6S1043 | 13 | |||||||
| D12S391 | 17 | 21 | 22 | |||||
| D2S441 | 11 | 12 | ||||||
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
FAQ
Which is better for studying SLC16A7 function, SLC16A7 Knockout HCT 116 Cell Line or SLC16A7 overexpression HCT 116 Cell Line?
The choice depends on whether you are studying SLC16A7 (MCT2)'s role as a high-affinity monocarboxylate transporter or its specific contributions distinct from MCT1 (SLC16A1) and MCT4 (SLC16A3). The Knockout line is the standard tool for asking whether MCT2 is required for lactate, pyruvate, and ketone body transport in contexts where MCT2 dominates over other MCT family members. Overexpression is useful for studying MCT2 in heterologous systems or for testing inhibitor selectivity.
For monocarboxylate transport research, the EDITGENE MCT2 Knockout in HCT 116 enables study of high-affinity lactate handling in a colorectal cancer context. MCT2 has higher affinity for lactate than MCT1/MCT4 (Km ~0.7 mM vs ~5 mM and ~30 mM respectively) — making it particularly relevant in tissues where physiological lactate concentrations are low. Rescue with wild-type or transport-deficient MCT2 enables structure-function studies. Note that MCT2 requires embigin (EMB), not basigin (CD147), as its ancillary protein.
What are the application scenarios for this model?
Primary applications:
• High-affinity monocarboxylate uptake: ³H-lactate, ³H-pyruvate uptake at low substrate concentrations to characterize MCT2 high-affinity transport.
• Embigin (EMB) ancillary protein studies: co-immunoprecipitation and trafficking analysis given MCT2's dependence on embigin rather than basigin.
• MCT family comparison: parallel analysis with MCT1 (SLC16A1) and MCT4 (SLC16A3) for paralog-specific functions in cancer metabolism.
• MCT inhibitor specificity: critical genetic control for AZD3965 (MCT1-selective) and other MCT-targeting compounds.
EDITGENE recommends this model for researchers investigating monocarboxylate transport, cancer lactate handling, and MCT-targeted pharmacology.
Is this SLC16A7 Knockout HCT 116 Cell Line compatible with overexpression rescue experiments?
Yes. MCT2 rescue experiments require attention to embigin partnership:
• Construct design: use a codon-modified SLC16A7 sequence with a small C-terminal tag (FLAG, HA). MCT2 has 12 transmembrane domains.
• Embigin partnership: MCT2 requires embigin (EMB), not basigin (CD147), for surface trafficking — confirm embigin expression in rescue cells or co-express embigin for full activity.
• Transport-deficient rescue: substrate-binding pocket mutations enable structure-function studies.
• Functional readout: rescue should restore high-affinity monocarboxylate uptake at low substrate concentrations (where MCT2 dominates over MCT1).
HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.